Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clifton C Mo

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|October 1, 2019
Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futileClifton C Mo, Paul G Richardson
European Neurology|June 16, 2007
IVIG for thymoma-associated pseudo-obstruction: report of successful treatmentDavid L Greenburg, Clifton C Mo, Paul A Hemmer
British Journal of Haematology|June 6, 2020
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?Dickran Kazandjian, Clifton C Mo, Ola Landgren, et al.
Journal of Clinical Medicine|May 2, 2015
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid LeukemiaNestor R Ramos, Clifton C Mo, Judith E Karp, et al.
Cancers|December 23, 2023
Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted TherapyClifton C Mo, Monique A Hartley-Brown, Shonali Midha, et al.
Haematologica|February 22, 2024
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responsesMehmet H Kocoglu, Paul G Richardson, Clifton C Mo, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2025
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in MyelomaClifton C Mo, Yuxin Liu, Monique A Hartley-Brown, et al.
Seminars in Oncology|February 2, 2022
The emerging importance and evolving understanding of clonal hematopoiesis in multiple myelomaChristin B DeStefano, Steven J Gibson, Adam S Sperling, et al.
Cancers|March 28, 2024
Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple MyelomaMonique A Hartley-Brown, Clifton C Mo, Omar Nadeem, et al.
Expert Review of Hematology|May 14, 2021
Selinexor for the treatment of patients with previously treated multiple myelomaClifton C Mo, Sundar Jagannath, Ajai Chari, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|October 1, 2019
Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futileClifton C Mo, Paul G Richardson
European Neurology|June 16, 2007
IVIG for thymoma-associated pseudo-obstruction: report of successful treatmentDavid L Greenburg, Clifton C Mo, Paul A Hemmer
British Journal of Haematology|June 6, 2020
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?Dickran Kazandjian, Clifton C Mo, Ola Landgren, et al.
Journal of Clinical Medicine|May 2, 2015
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid LeukemiaNestor R Ramos, Clifton C Mo, Judith E Karp, et al.
Cancers|December 23, 2023
Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted TherapyClifton C Mo, Monique A Hartley-Brown, Shonali Midha, et al.
Haematologica|February 22, 2024
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responsesMehmet H Kocoglu, Paul G Richardson, Clifton C Mo, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2025
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in MyelomaClifton C Mo, Yuxin Liu, Monique A Hartley-Brown, et al.
Seminars in Oncology|February 2, 2022
The emerging importance and evolving understanding of clonal hematopoiesis in multiple myelomaChristin B DeStefano, Steven J Gibson, Adam S Sperling, et al.
Cancers|March 28, 2024
Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple MyelomaMonique A Hartley-Brown, Clifton C Mo, Omar Nadeem, et al.
Expert Review of Hematology|May 14, 2021
Selinexor for the treatment of patients with previously treated multiple myelomaClifton C Mo, Sundar Jagannath, Ajai Chari, et al.
Pageof 3